BSE Live
Apr 20, 16:01Prev. Close
350.85
Open Price
356.45
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 20, 15:47Prev. Close
351.20
Open Price
351.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Unichem Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 1,688.80 | 1,392.62 | 1,030.51 | 919.18 | 1,078.52 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 1,688.80 | 1,392.62 | 1,030.51 | 919.18 | 1,078.52 | |
| Total Operating Revenues | 1,735.70 | 1,442.17 | 1,072.43 | 942.93 | 1,123.97 | |
| Other Income | 40.83 | 30.39 | 41.85 | 42.07 | 47.37 | |
| Total Revenue | 1,776.53 | 1,472.55 | 1,114.28 | 984.99 | 1,171.34 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 829.77 | 716.92 | 500.34 | 434.92 | 449.14 | |
| Purchase Of Stock-In Trade | 0.85 | 0.91 | 1.53 | 1.35 | 0.54 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -33.33 | -26.36 | 22.01 | -52.79 | -16.73 | |
| Employee Benefit Expenses | 287.51 | 283.14 | 270.86 | 250.79 | 234.04 | |
| Finance Costs | 7.62 | 10.42 | 9.38 | 2.07 | 1.30 | |
| Depreciation And Amortisation Expenses | 108.41 | 105.46 | 105.98 | 83.19 | 75.89 | |
| Other Expenses | 397.02 | 416.63 | 367.19 | 344.15 | 361.52 | |
| Total Expenses | 1,597.85 | 1,507.13 | 1,280.71 | 1,071.74 | 1,105.70 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 178.68 | -34.57 | -166.43 | -86.75 | 65.65 | |
| Exceptional Items | 4.00 | -57.61 | -112.66 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 182.68 | -92.18 | -279.09 | -86.75 | 65.65 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 19.72 | 0.00 | 20.61 | -31.56 | 10.94 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.24 | 0.62 | |
| Total Tax Expenses | 19.72 | 0.00 | 20.61 | -31.32 | 11.56 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 162.96 | -92.18 | -299.70 | -55.43 | 54.08 | |
| Profit/Loss From Continuing Operations | 162.96 | -92.18 | -299.70 | -55.43 | 54.08 | |
| Profit/Loss For The Period | 162.96 | -92.18 | -299.70 | -55.43 | 54.08 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 23.15 | -13.09 | -42.57 | -7.87 | 7.68 | |
| Diluted EPS (Rs.) | 23.08 | -13.09 | -42.57 | -7.87 | 7.68 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 28.16 | 28.16 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 200.00 | 200.00 |
10.02.2026
Unichem Labs Consolidated December 2025 Net Sales at Rs 521.17 crore, down 2.24% Y-o-Y
09.02.2026
Unichem Labs Standalone December 2025 Net Sales at Rs 314.90 crore, down 29.68% Y-o-Y
03.02.2026
17.11.2025
Unichem Labs Consolidated September 2025 Net Sales at Rs 578.96 crore, up 25.27% Y-o-Y
10.02.2026
Unichem Labs Consolidated December 2025 Net Sales at Rs 521.17 crore, down 2.24% Y-o-Y
09.02.2026
Unichem Labs Standalone December 2025 Net Sales at Rs 314.90 crore, down 29.68% Y-o-Y
17.11.2025
Unichem Labs Consolidated September 2025 Net Sales at Rs 578.96 crore, up 25.27% Y-o-Y
12.08.2025
Unichem Labs Consolidated June 2025 Net Sales at Rs 526.60 crore, up 17.96% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth